

- patients with hypertrophic cardiomyopathy. *Anatol J Cardiol* 2018; 20: 165-73.
- Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. *Circulation* 2008; 118: 1541-9.
 - Rowin EJ, Maron BJ, Haas TS, Garberich RF, Wang W, Link MS, et al. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications 85 for Risk Stratification and Management. *J Am Coll Cardiol* 2017; 69: 761-73.
 - Pusuroglu H, Akgul O, Erturk M, Bolat I, Tasbulak O, Ornek V, et al. Assessment of relationship between galectin-3 and ambulatory ECG-based microvolt T-wave alternans in sustained systolic-diastolic hypertension patients. *Blood Press Monit* 2016; 21: 265-70.
 - Bloomfield DM, Steinman RC, Namerow PB, Parides M, Davidenko J, Kaufman ES, et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. *Circulation* 2004; 110: 1885-9.
 - Chow T, Kereiakes DJ, Onufer J, Woelfel A, Gursoy S, Peterson BJ, et al.; MASTER Trial Investigators. Does microvolt T-wave alternans testing predict ventricular tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients) trial. *J Am Coll Cardiol* 2008; 52: 1607-15.
 - de Oliveira Antunes M, Samesima N, Pereira Filho HG, Matsumoto AY, Verrier RL, Pastore CA, et al. Exercise-induced quantitative microvolt T-wave alternans in hypertrophic cardiomyopathy. *J Electrocardiol* 2017; 50: 184-90.
 - Momiyama Y, Hartikainen J, Nagayoshi H, Albrecht P, Kautzner J, Saumarez RC, et al. Exercise-induced T-wave alternans as a marker of high risk in patients with hypertrophic cardiomyopathy. *Jpn Circ J* 1997; 61: 650-6.
 - Kuroda N, Ohnishi Y, Yoshida A, Kimura A, Yokoyama M. Clinical significance of T-wave alternans in hypertrophic cardiomyopathy. *Circ J* 2002; 66: 457-62.

Address for Correspondence: Dr. Sinem Özyılmaz,
Mehmet Akif Ersoy Göğüs ve
Kalp Damar Cerrahisi Eğitim ve Araştırma Hastanesi,
Kardiyoloji Bölümü,
İstanbul-Türkiye
Phone: +90 212 692 20 00-1134
E-mail: drsinemozbey@gmail.com
©Copyright 2018 by Turkish Society of Cardiology - Available online
at www.anatoljcardiol.com

Non-ergot dopamine agonists and heart failure

To the Editor,

We have read with great interest the article published by Erken Pamukcu et al. (1) about the effects of different non-ergot dopamine agonists on cardiac functions in patients with Parkinson's disease. Authors demonstrated that non-ergot dopamine

agonists, ropirinole and pramipexole, are safe drugs for cardiac systolic and diastolic functions (1).

There are conflicting data regarding the relationship between non-ergot dopamine agonists and heart failure. FDA released a safety concern because of a possible association between non-ergot dopamine agonists and increased heart failure incidence in 2012. These concerns were the result of observational studies, after which randomized controlled studies were designed and non-ergot dopamine agonists were established as safe drugs for cardiovascular system. In the current era, although previous studies have suggested that non-ergot dopamine agonists are related to increased heart failure incidence, recent studies and meta-analyses have shown no such significant relationship and have reported that non-dopamine agonists can be safely used in patients with heart failure (2).

Heart failure is classified according to systolic functions, and heart failure with preserved ejection fraction (HFpEF) is diagnosed by the presence of symptoms related to heart failure and elevated BNP levels (3). In this study, non-dopamine agonists did not cause deleterious changes in the echocardiographic systolic and diastolic parameters; however, it is difficult to implicate that these drugs do not cause heart failure by the lights of these results. We believe that it would be better if BNP levels were measured and patients were questioned for symptoms of heart failure so as to reveal the association between heart failure and non-dopamine agonists.

Yusuf Ziya Şener, Metin Okşul, Cem Çötel
Department of Cardiology, Faculty of Medicine, Hacettepe University,
Ankara-Turkey

References

- Erken Pamukcu H, Gerede Uludağ DM, Tekin Tak B, Sorgun MH, Efe TH, Acıbuca A, et al. Evaluation of the effect of non-ergot dopamine agonists on left ventricular systolic function with speckle tracking echocardiography. *Anatol J Cardiol* 2018; 20: 213-9. [CrossRef]
- De Vecchis R, Cantatrione C, Mazzei D, Baldi C, Di Maio M. Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson's Disease Patients: A Meta-Analysis of Randomized Controlled Trials. *J Clin Med Res* 2016; 8: 449-60. [CrossRef]
- Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al.; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016; 18: 891-975.

Address for Correspondence: Dr. Yusuf Ziya Şener,
Hacettepe Üniversitesi Tıp Fakültesi,
Kardiyoloji Anabilim Dalı,
Ankara-Türkiye
Phone: +90 312 305 28 15
E-mail: yzsener@yahoo.com.tr
©Copyright 2018 by Turkish Society of Cardiology - Available online
at www.anatoljcardiol.com
DOI:10.14744/AnatolJCardiol.2018.76299

